weight loss/neoplasms

FIELD OF THE INVENTION The present invention relates to transdermal devices and methods for controllable dispensing of a nutraceutical or an active substance such as a chemical substance, a medication, a drug, a stimulant or the like, to a human or other mammal for purposes of promoting longevity,

FIELD OF THE INVENTION The present invention relates to transdermal devices and methods for controllable dispensing of a nutraceutical or an active substance such as a chemical substance, a medication, a drug, a stimulant or the like, to a human or other mammal for purposes of promoting longevity,

FIELD OF THE INVENTION The present invention relates to transdermal devices and methods for controllable dispensing of a nutraceutical or an active substance such as a chemical substance, a medication, a drug, a stimulant or the like, to a human or other mammal for purposes of promoting longevity,

FIELD OF THE INVENTION The present invention relates to transdermal devices and methods for controllable dispensing of a nutraceutical or an active substance such as a chemical substance, a medication, a drug, a stimulant or the like, to a human or other mammal for purposes of promoting longevity,

FIELD OF THE INVENTION The present invention relates to transdermal devices and methods for controllable dispensing of a nutraceutical or an active substance such as a chemical substance, a medication, a drug, a stimulant or the like, to a human or other mammal for purposes of promoting longevity,

BACKGROUND OF THE INVENTION The present invention relates to a method for reducing fat and blood lipid levels in humans. Obesity is defined as a body mass index of greater than 30, whereas overweight is defined as having a body mass index of greater than 25. Approximately 19% Americans are obese,

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5

TECHNICAL FIELD The present invention relates to oxprenolol compositions and uses thereof, including uses of the oxprenolol compositions for treating cancer. BACKGROUND Cancer is the second most common cause of death in the United States, exceeded only by heart disease. In the United States, cancer

BACKGROUND Gastrokine-1 (Gkn-1) is a stomach protein that protects the gastrointestinal (GI) tract. Previously this protein was designated AMP-18. SUMMARY Gkn-1 knockout mice (Gkn-1-/-) were generated. Recombinant Gkn-1 peptide antibodies were produced to investigate this protein and its role in the

FIELD OF THE INVENTION The present invention relates to new immunoconjugates comprising an anticancer agent and a monoclonal antibody and use of such immunoconjugates for killing or inhibiting the growth of matriptase expressing cancer cells, including but not limited to those of multiple myeloma

FIELD OF THE INVENTION The present invention relates to new immunoconjugates comprising an anticancer agent and a monoclonal antibody and use of such immunoconjugates for killing or inhibiting the growth of matriptase expressing cancer cells, including but not limited to those of multiple myeloma

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to the use of protective agents in cancer chemotherapy in human and animal subjects. Protective agents are compounds that prevent, reduce, or otherwise ameliorate the toxic side effects of anti-cancer

BACKGROUND OF THE INVENTION The present invention relates to a method for reducing fat and blood lipid levels in humans. Obesity is defined as a body mass index of greater than 30, whereas overweight is defined as having a body mass index of greater than 25. Approximately 19% Americans are obese,

CROSS REFERENCE TO RELATED APPLICATION This application claims priority under 35 U.S.C. .sctn.119(e) to U.S. Provisional Application No. 61/211,527, filed Mar. 31, 2009, which application is incorporated by reference herein in its entirety. FIELD OF INVENTION The invention relates to leptin

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to the use of compounds which have specific or selective agonist like activity on RAR.sub..alpha. retinoid receptors for treatment of diseases and conditions which respond to treatment by such retinoids. More